Related Experiment Video

Updated: Nov 24, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.7K

NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura

Mary Hughes1, Carl Prescott1, Nicole Elliott1

  • 1Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester M1 4BT, UK.

The Lancet. Haematology
|December 28, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

753
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.2K

Related Experiment Videos

Last Updated: Nov 24, 2025

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.7K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

753
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.2K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

121
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
121
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K

Articles linked to this work by shared authors, journal, and citation graph.

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.

Diabetes, obesity & metabolism·2026

Participants' experiences of living with cystic fibrosis related diabetes and using a hybrid closed-loop system to support self-management: qualitative study.

BMC endocrine disorders·2026

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data.

Health technology assessment (Winchester, England)·2026

An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders.

Nature. Mental health·2026

Cognitive Dissonance in Nursing: A Mixed Systematic Review of Its Impact and Coping Strategies.

Journal of advanced nursing·2026

Benchmark Performance of Emergency Medicine Residents in Pediatric Resuscitation: Are We Optimizing Education and Does Length of Training Matter?

AEM education and training·2026

At the heart of unmet need: TP53 myeloid neoplasms.

The Lancet. Haematology·2026

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.

The Lancet. Haematology·2026

Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2).

The Lancet. Haematology·2026

Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.

The Lancet. Haematology·2026

Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.

The Lancet. Haematology·2026

High time for risk-adapted treatment in mantle cell lymphoma.

The Lancet. Haematology·2026

Getting comfortable: clonal haematopoiesis creates a senescent niche for expansion.

Cancer research·2026

A ratiometric dual "turn-on" electrochemical strategy for reliable HbA1c level determination.

Chemical communications (Cambridge, England)·2026

Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial.

European stroke journal·2026

Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination.

Journal of clinical lipidology·2026

Subarachnoid haemorrhage in paediatric hereditary haemorrhagic telangiectasia: a case report and literature review.

British journal of neurosurgery·2026

TET 2-mutant clonal hematopoiesis is associated with peripheral bypass graft occlusion: A multicenter retrospective cohort pilot study.

JVS-vascular science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us